Therefore, this study aimed to (1) determine the proportion of patients with high-risk prostate cancer (HR-PCa) who experienced spontaneous PSA decline after CIRT, following fulfillment of the Phoenix criteria, and (2) assess the validity of those criteria for guiding salvage treatment initiation. The gene discussed is KLK3; the disease is prostate cancer.